Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 510
  • Home
  • Print this page
  • Email this page
Year : 2017  |  Volume : 22  |  Issue : 1  |  Page : 21

Study of the regulatory promoter polymorphism (−938C>A) of B-cell lymphoma 2 gene in breast cancer patients of Mazandaran province in Northern Iran

1 Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Sari, Iran
2 Department of Surgery, School of Medicine, Babol University of Medical Sciences, Babol, Iran

Correspondence Address:
Ali Barzegar
Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Km 9 Darya Boulevard, P.O. Box 578, Sari
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1735-1995.200269

Rights and Permissions

Background: The incidence rate of breast cancer has been dramatically increasing since the last decade in Iran, and it is now one of the most common female malignant tumors. B-cell lymphoma 2 (BCL2) family is the most important regulator of apoptosis, and −938C>A single nucleotide polymorphism (SNP) of BCL2 gene promoter has been demonstrated to influence breast cancer susceptibility. In this research, we study the effect of −938C>A allelic variants on breast cancer risk in Mazandaran province at the North of Iran. Materials and Methods: This analysis performed on 120 breast cancer patients who underwent surgery in some referenced hospitals at Mazandaran province along with 130 healthy individuals as a control. DNA extracted from peripheral blood samples was applied in polymerase chain reaction-single-strand conformation polymorphism analysis to determine −938C>A genotype. The association of the −938C>A genotype and breast cancer risk as well as clinicopathological characters were analyzed by logistic regression method. Results: Results showed that genotype frequency of AA, AC, and CC genotypes was 10%, 62%, and 28% for case and 28%, 50%, and 22% in control group, respectively. In the logistic regression model, BCL2 − 938C/A variant genotype AA was associated with a decreased risk of breast cancer (P = 0.041) by 0.31-fold (odds ratio = 0.31, confidence interval = 0.091–0.909) compared to CC genotype. However, no significant association found between −938C>A genotype and clinicopathological characters. Conclusion: The study showed that AA genotype of BCL2 gene (−938C>A) is associated with decreased susceptibility to breast cancer. Hence, investigating the −938C>A SNP of BCL2 gene promoter could be an appropriate molecular marker to determine individual sensitivity to breast cancer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded160    
    Comments [Add]    
    Cited by others 1    

Recommend this journal